Nuvation Bio prices upsized USD 250 million convertible senior notes offering due 2032

NUVATION BIO INC

NUVB

0.00

Nuvation Bio priced an upsized offering of USD 250 million of 0.75% Convertible Senior Notes due 2032.
Offering increased from USD 200 million; underwriters hold a 30-day option for up to an additional USD 37.5 million of notes.
Net proceeds estimated at about USD 241.2 million, or about USD 277.6 million if the over-allotment option is fully exercised.
Proceeds earmarked for capped call costs, full repayment of the senior secured loan agreement, general corporate purposes.
Notes convertible at an initial price of about USD 7.84 per share; issuer may redeem from July 6, 2029 under share-price conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606252358PR_NEWS_USPR_____NY93004) on June 26, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.